- Home
- NVS vs AZN Comparison
NVS vs AZN Comparison
Compare NVS & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NVS | AZN |
|---|---|---|
| Founded | 1895 | 1992 |
| Country | Switzerland | United Kingdom |
| Employees | 75267 | 96100 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 286.9B | 311.3B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NVS | AZN |
|---|---|---|
| Price | $151.24 | $200.68 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $144.00 | N/A |
| AVG Volume (30 Days) | ★ 1.8M | 1.7M |
| Earning Date | 04-28-2026 | 04-28-2026 |
| Dividend Yield | ★ 2.02% | 1.58% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.34 | $10.35 |
| Revenue Next Year | $5.14 | $6.43 |
| P/E Ratio | ★ $23.13 | $31.91 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $97.72 | $61.24 |
| 52 Week High | $170.46 | $212.71 |
Technical Indicators
Market Signals| Indicator | NVS | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 44.58 | 62.42 |
| Support Level | $145.30 | $182.39 |
| Resistance Level | $158.80 | $211.32 |
| Average True Range (ATR) | 2.19 | 3.58 |
| MACD | 0.32 | 0.60 |
| Stochastic Oscillator | 52.34 | 80.79 |
Price Performance
Historical ComparisonAbout NVS Novartis AG
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.